Up-and-Comers: 4 Trends in Big Pharma’s Pipeline

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn
Source: Thinkstock

Source: Thinkstock

The year 2014 has been full of big moves in the pharmaceutical industry, with Big Pharma companies engaging in seemingly rapid-fire merger and acquisition deals in an effort to reorder and reorganize its businesses. More and more, pharmaceutical companies are focused on snatching up smaller competitors that are proven innovators in a specific field, and the focus seems to be on establishing the very best R&D teams in specific, viable areas of research.

The year 2014 has also been plagued with an ongoing stream of doom and gloom surrounding the industry’s ever-persistent, ever-approaching “patent cliff,” along with concerns regarding the Big Pharma’s viability now that blockbusters are harder and harder to come by. But there are reassuring words to be had, particularly if you keep the bigger picture in mind. IHS analyst Gustav Ando, who spoke with Britain’s The Guardian in a recent report, says that, “The pharma industry is probably one of the most adaptable industries out there. Very few industries are forced to completely reinvent themselves.”

While there is still much of the year to account for, already trends seem to be emerging for 2014. Specialty drugs are high on our list, with generics (and the drama it creates) also likely to play an important role throughout the rest of the year. Continue on to see the full list.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business